Arcus Biosciences (RCUS) Operating Margin (2017 - 2026)
Arcus Biosciences' (RCUS) quarterly Operating Margin came in at 788.24% in Q1 2026, down 35252.0% year-on-year from N/an in Q1 2025, and down 128.17% quarter-over-quarter from 345.45% in Q4 2025.
Arcus Biosciences (RCUS) Operating Margin (2017 - 2026) Analysis & Trends
Arcus Biosciences' Operating Margin history runs 10 years deep, the most recent figure standing at 788.24% for Q1 2026.
- On a quarterly basis, Operating Margin fell 35252.0% year-over-year to 788.24% in Q1 2026; TTM through Mar 2026 was 168.64%, a 14058.0% increase from a year earlier, with the FY2025 full-year figure at 156.28%, down 2837.0% from the prior year.
- Operating Margin declined to 788.24% in Q1 2026 per RCUS's latest filing, from 345.45% in the prior quarter.
- Across five years, Operating Margin topped out at 5.0% in Q2 2025 and bottomed at 788.24% in Q1 2026.
- The 5-year median for Operating Margin is 286.21% (2023), against an average of 329.77%.
- Across the five-year window, Operating Margin surged 61375 bps in 2022 and sank 43235 bps in 2023, its largest moves.
- Year by year, Operating Margin stood at 217.65% in 2022, then plunged by 199 bps to 650.0% in 2023, then surged by 39 bps to 396.15% in 2024, then advanced by 13 bps to 345.45% in 2025, then sank by 128 bps to 788.24% in 2026.
- Per Business Quant, the three latest RCUS Operating Margin figures stand at 788.24% (Q1 2026), 345.45% (Q4 2025), and 546.15% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arcus Biosciences | 3.73 Bn | 2.90 Bn | - | -788.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -788.24% |
| Dec 31, 2025 | -345.45% |
| Sep 30, 2025 | -546.15% |
| Jun 30, 2025 | -5.00% |
| Mar 31, 2025 | -435.71% |
| Dec 31, 2024 | -396.15% |
| Sep 30, 2024 | -218.75% |
| Jun 30, 2024 | -271.79% |
| Mar 31, 2024 | -11.03% |
| Dec 31, 2023 | -650.00% |
| Sep 30, 2023 | -250.00% |
| Jun 30, 2023 | -286.21% |
| Mar 31, 2023 | -344.00% |
| Dec 31, 2022 | -217.65% |
| Sep 30, 2022 | -212.12% |
| Jun 30, 2022 | -255.56% |
| Mar 31, 2022 | -372.22% |
| Dec 31, 2021 | 79.25% |
| Sep 30, 2021 | -825.87% |
| Jun 30, 2021 | -804.74% |